Mylan ROE 2006-2018 | MYL

Current and historical return on equity (ROE) values for Mylan (MYL) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Mylan ROE for the three months ending September 30, 2018 was 19.39%.
Mylan ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $0.55B $12.07B 4.30%
2018-06-30 $0.46B $12.21B 3.52%
2018-03-31 $0.72B $13.18B 5.44%
2017-12-31 $0.70B $13.31B 5.44%
2017-09-30 $0.87B $13.29B 7.11%
2017-06-30 $0.66B $12.83B 5.57%
2017-03-31 $0.53B $11.66B 4.74%
2016-12-31 $0.48B $11.12B 4.41%
2016-09-30 $0.26B $11.83B 2.44%
2016-06-30 $0.81B $10.33B 8.02%
2016-03-31 $0.81B $10.28B 8.18%
2015-12-31 $0.85B $9.77B 8.88%
2015-09-30 $0.84B $9.82B 10.62%
2015-06-30 $0.91B $9.57B 14.41%
2015-03-31 $0.87B $9.09B 18.19%
2014-12-31 $0.93B $3.28B 28.09%
2014-09-30 $0.92B $3.41B 28.50%
2014-06-30 $0.58B $3.35B 18.21%
2014-03-31 $0.63B $3.19B 20.54%
2013-12-31 $0.62B $2.96B 20.76%
2013-09-30 $0.61B $3.23B 19.52%
2013-06-30 $0.66B $2.95B 20.54%
2013-03-31 $0.62B $2.89B 18.95%
2012-12-31 $0.64B $3.36B 18.37%
2012-09-30 $0.61B $3.62B 17.24%
2012-06-30 $0.55B $3.20B 15.85%
2012-03-31 $0.56B $3.78B 15.31%
2011-12-31 $0.54B $3.51B 14.49%
2011-09-30 $0.41B $3.49B 11.00%
2011-06-30 $0.36B $3.88B 9.65%
2011-03-31 $0.27B $3.92B 7.57%
2010-12-31 $0.22B $3.62B 6.70%
2010-09-30 $0.22B $3.54B 6.98%
2010-06-30 $0.08B $2.98B 2.46%
2010-03-31 $0.08B $3.18B 2.70%
2009-12-31 $0.09B $3.15B 3.16%
2009-09-30 $0.03B $3.07B 1.19%
2009-06-30 $0.26B $2.91B 9.04%
2009-03-31 $0.18B $2.65B 6.31%
2008-12-31 $-0.34B $2.79B -11.15%
2008-09-30 $-1.60B $2.98B -50.65%
2008-06-30 $-1.64B $3.13B -56.53%
2008-03-31 $-1.54B $3.16B -60.56%
2007-12-31 $-1.16B $3.40B -53.74%
2007-09-30 $0.29B $1.89B 18.48%
2007-06-30 $0.22B $1.73B 16.34%
2007-03-31 $0.22B $1.65B 19.04%
2006-12-31 $0.29B $1.10B 31.09%
2006-09-30 $0.20B $0.96B 23.94%
2006-06-30 $0.16B $0.87B 19.70%
2006-03-31 $0.13B $0.79B 11.93%
2005-12-31 $0.13B $0.76B 9.56%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $15.680B $11.908B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $51.359B 8.82
Teva Pharmaceutical Industries (TEVA) Israel $19.310B 5.92
Bausch Health Cos (BHC) Canada $8.440B 6.11
Dr Reddy's Laboratories (RDY) India $5.963B 23.78
Supernus Pharmaceuticals (SUPN) United States $1.944B 18.42
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.737B 2.90
Amphastar Pharmaceuticals (AMPH) United States $0.973B 105.55
Homology Medicines (FIXX) United States $0.918B 0.00
Assembly Biosciences (ASMB) United States $0.616B 0.00
Akorn (AKRX) United States $0.543B 0.00
CymaBay Therapeutics (CBAY) United States $0.521B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.421B 0.00
Voyager Therapeutics (VYGR) United States $0.364B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.265B 0.00
Sol-Gel Technologies (SLGL) Israel $0.115B 0.00
Teligent (TLGT) United States $0.097B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.083B 0.00
Aevi Genomic Medicine (GNMX) United States $0.077B 0.00
Acasti Pharma (ACST) Canada $0.056B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.055B 0.00
Evoke Pharma (EVOK) United States $0.046B 0.00
Agile Therapeutics (AGRX) United States $0.029B 0.00
China Pharma Holdings (CPHI) China $0.011B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.005B 0.00